Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Phase 3 Completed 771 enrolled Materia Medica Holding

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.

Timeline

Start: 2022-04-29
Primary completion: 2023-08-18
Completion: 2023-08-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Raphamin	Unknown	1 unknown	Oral

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Summary

Timeline

Drugs

Indications